Ignite Creation Date:
2025-12-24 @ 12:44 PM
Ignite Modification Date:
2025-12-28 @ 12:08 PM
Study NCT ID:
NCT02913261
Status:
COMPLETED
Last Update Posted:
2023-02-08
First Post:
2016-09-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-03-10
Start Date Type:
ACTUAL
Primary Completion Date:
2019-06-24
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-04-23
Completion Date Type:
ACTUAL
First Submit Date:
2016-09-18
First Submit QC Date:
None
Study First Post Date:
2016-09-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-10-23
Results First Submit QC Date:
None
Results First Post Date:
2023-02-08
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-05-09
Last Update Post Date:
2023-02-08
Last Update Post Date Type:
ACTUAL